全文获取类型
收费全文 | 4299379篇 |
免费 | 373269篇 |
国内免费 | 15473篇 |
专业分类
耳鼻咽喉 | 61652篇 |
儿科学 | 133587篇 |
妇产科学 | 112602篇 |
基础医学 | 655207篇 |
口腔科学 | 120932篇 |
临床医学 | 400194篇 |
内科学 | 781271篇 |
皮肤病学 | 105053篇 |
神经病学 | 370452篇 |
特种医学 | 171472篇 |
外国民族医学 | 912篇 |
外科学 | 658008篇 |
综合类 | 126109篇 |
现状与发展 | 58篇 |
一般理论 | 2578篇 |
预防医学 | 366443篇 |
眼科学 | 101741篇 |
药学 | 301857篇 |
24篇 | |
中国医学 | 11356篇 |
肿瘤学 | 206613篇 |
出版年
2021年 | 56429篇 |
2020年 | 37496篇 |
2019年 | 59133篇 |
2018年 | 76021篇 |
2017年 | 59128篇 |
2016年 | 65538篇 |
2015年 | 78793篇 |
2014年 | 114321篇 |
2013年 | 179956篇 |
2012年 | 118402篇 |
2011年 | 121401篇 |
2010年 | 125372篇 |
2009年 | 129462篇 |
2008年 | 108572篇 |
2007年 | 114622篇 |
2006年 | 124509篇 |
2005年 | 119237篇 |
2004年 | 119934篇 |
2003年 | 110637篇 |
2002年 | 101187篇 |
2001年 | 154897篇 |
2000年 | 150762篇 |
1999年 | 140070篇 |
1998年 | 72053篇 |
1997年 | 68357篇 |
1996年 | 66178篇 |
1995年 | 61915篇 |
1994年 | 55824篇 |
1993年 | 51856篇 |
1992年 | 103739篇 |
1991年 | 99089篇 |
1990年 | 94195篇 |
1989年 | 91760篇 |
1988年 | 85377篇 |
1987年 | 83833篇 |
1986年 | 79514篇 |
1985年 | 77939篇 |
1984年 | 65967篇 |
1983年 | 58882篇 |
1982年 | 48156篇 |
1981年 | 44896篇 |
1980年 | 42175篇 |
1979年 | 57826篇 |
1978年 | 47036篇 |
1977年 | 41600篇 |
1976年 | 38661篇 |
1975年 | 37848篇 |
1974年 | 42416篇 |
1973年 | 40548篇 |
1972年 | 38019篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
861.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献862.
Understanding why persons with human immunodeficiency virus (HIV) have accelerated atherosclerosis and its sequelae, including coronary artery disease (CAD) and myocardial infarction, is necessary to provide appropriate care to a large and aging population with HIV. In this review, we delineate the diverse pathophysiologies underlying HIV-associated CAD and discuss how these are implicated in the clinical manifestations of CAD among persons with HIV. Several factors contribute to HIV-associated CAD, with chronic inflammation and immune activation likely representing the primary drivers. Increased monocyte activation, inflammation, and hyperlipidemia present in chronic HIV infection also mirror the pathophysiology of plaque rupture. Furthermore, mechanisms central to plaque erosion, such as activation of toll-like receptor 2 and formation of neutrophil extracellular traps, are also abundant in HIV. In addition to inflammation and immune activation in general, persons with HIV have a higher prevalence than uninfected persons of traditional cardiovascular risk factors, including dyslipidemia, hypertension, insulin resistance, and tobacco use. Antiretroviral therapies, although clearly necessary for HIV treatment and survival, have had varied effects on CAD, but newer generation regimens have reduced cardiovascular toxicities. From a clinical standpoint, this mix of risk factors is implicated in earlier CAD among persons with HIV than uninfected persons; whether the distribution and underlying plaque content of CAD for persons with HIV differs considerably from uninfected persons has not been definitively studied. Furthermore, the role of cardiovascular risk estimators in HIV remains unclear, as does the role of traditional and emerging therapies; no trials of CAD therapies powered to detect clinical events have been completed among persons with HIV. 相似文献
863.
864.
865.
866.
867.
Canadian Journal of Anesthesia/Journal canadien d'anesthésie - 相似文献
868.
869.
C. M. de Bont N. Eerden W. C. Boelens G. J. M. Pruijn 《Clinical and experimental immunology》2020,199(1):1-8
Neutrophils can form neutrophil extracellular traps (NETs) to capture microbes and facilitate their clearance. NETs consist of decondensed chromatin decorated with anti-microbial proteins. Here, we describe the effect of neutrophil proteases on the protein content of NETs. We show that the neutrophil serine proteases degrade several neutrophil proteins associated with NETs. Interestingly, the anti-bacterial proteins associated with NETs, such as myeloperoxidase, calgranulin B and neutrophil elastase (NE), seem to be less susceptible to proteolytic degradation than other NET proteins, such as actin and MNDA. NETs have been proposed to play a role in autoimmune reactions. Our data demonstrate that a large number of the autoepitopes of NET proteins that are recognized by autoantibodies produced by systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients are also removed by the proteases. In conclusion, neutrophil serine proteases have a major impact on the NET proteome and the proteolytic changes of NET-associated proteins may counteract autoimmune reactions to NET components. 相似文献
870.
Nicola Flaum Emma J. Crosbie Richard J. Edmondson Miriam J. Smith Dafydd G. Evans 《Clinical genetics》2020,97(1):54-63
Ovarian cancer is the fourth most common cause of cancer-related death in women in the developed world, and one of the most heritable cancers. One of the most significant risk factors for epithelial ovarian cancer (EOC) is a family history of breast and/or ovarian cancer. Combined risk factors can be used in models to stratify risk of EOC, and aid in decisions regarding risk-reduction strategies. Germline pathogenic variants in EOC susceptibility genes including those involved in homologous recombination and mismatch repair pathways are present in approximately 22% to 25% of EOC. These genes are associated with an estimated lifetime risk of EOC of 13% to 60% for BRCA1 variants and 10% to 25% for BRCA2 variants, with lower risks associated with remaining genes. Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) thought to explain an additional 6.4% of the familial risk of ovarian cancer, with 34 susceptibility loci identified to date. However, an unknown proportion of the genetic component of EOC risk remains unexplained. This review comprises an overview of individual genes and SNPs suspected to contribute to risk of EOC, and discusses use of a polygenic risk score to predict individual cancer risk more accurately. 相似文献